Nordic Issuing

Ongoing case

Scandinavian Real Heart AB

Back to all cases

Scandinavian Real Heart AB

16 Aug - 3 Sep 2021Rights issue

Swedish innovation power has given the world medical technology inventions such as the heart and lung machine, the pacemaker and the dialysis machine. The next big innovation is Realheart’s artificial heart. A Swedish patent that saves people and creates a life-affirming continuation of life.

The foundation for the company was laid by the doctor Azad Najar in 1999 when he started sketching an artificial heart that completely mimics the biological. In 2007, Azad co-founded Scandinavian Real Heart with two partners. The company develops an artificial heart that mimics the function of a natural heart, a so-called total artificial heart (TAH). The patented solution at Realheart TAH is developed to mimic the natural human heart’s blood flow pattern and function, which creates the possibility of a long-term solution for patients diagnosed with advanced heart failure. The artificial heart will be sold in combination with the equipment the patient needs: control unit, battery belt, batteries, chargers and cables. As well as equipment for the care provider at the hospital such as monitors and services (24-hour support hotline, service of peripherals, training of care teams, remote monitoring of data and cloud storage, etc. To create a life with maximum freedom of movement and comfort, there is great focus on reducing equipment size and create a soundless system which is now characteristic of Realheart TAH.High battery capacity and flexible solutions for carrying the equipment are more features that will enable the person to live a full life.

Read more on the company's website

The offer in summary

Record date: 12 August 2021

Subscription period: 16 August - 3 September 2021

Subscription price: 6,00 SEK per Unit

Preferential rights : The company's shareholders have a preferential right to subscribe for Units in the Rights Issue, whereby two (2) existing shares entitle to subscribe for one (1) Unit. Each Unit consists of one share and a free warrant of series 2021/2023: 1. The subscription price has been set at SEK 6.00 per Unit, corresponding to a total issue proceeds of approximately SEK 67.7 million if the Rights Issue is fully subscribed.

Warrants : Four (4) warrants of series 2021/2023: 1 are required to subscribe for one (1) new share in Realheart at a subscription price corresponding to 70 percent of the volume-weighted average price of the Company's share during the period from and including January 9, 2023 up to and including on January 27, 2023. Subscription of shares exercising warrants of series 2021/2023: 1 can take place during the period February 1, 2023 through February 28, 2023.

Trading in subscription rights on Spotlight Stock Market : 16 August - 31 August 2021


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.